Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Interest & Investment Income: 2011-2024

Historic Interest & Investment Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $48.1 million.

  • Agios Pharmaceuticals' Interest & Investment Income rose 2.37% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 60.20%. This contributed to the annual value of $48.1 million for FY2024, which is 44.20% up from last year.
  • Agios Pharmaceuticals' Interest & Investment Income amounted to $48.1 million in FY2024, which was up 44.20% from $33.3 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Interest & Investment Income registered a high of $48.1 million during FY2024, and its lowest value of $836,000 during FY2021.
  • In the last 3 years, Agios Pharmaceuticals' Interest & Investment Income had a median value of $33.3 million in 2023 and averaged $31.4 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 87.35% in 2021, then soared by 1,430.26% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Interest & Investment Income (Yearly) stood at $6.6 million in 2020, then plummeted by 87.35% to $836,000 in 2021, then spiked by 1,430.26% to $12.8 million in 2022, then spiked by 160.64% to $33.3 million in 2023, then soared by 44.20% to $48.1 million in 2024.